You are here
- Home
- Therapy Areas
- Oncology/Infection
A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Digoxin in Healthy Subjects When Administered Alone and in Combination With a Single Dose of Vandetanib (CAPRELSA) 300 mg
- Disease
- oncology
- Drug Name
- Caprelsa, vandetanib
- Generic Name
- ZD6474=Caprelsa=Vandetanib
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- I
- Start Date
- Jan 18, 1971
- Study Name
- D4200C00100
- Study Id
- D4200C00100
- ClinicalTrials.gov ID
- NCT01561781
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
